

SOURCE
DATATRANSPARENT
PROCESS

Unfolded protein response-induced ERdj3 secretion links ER stress to extracellular proteostasis

Joseph C Genereux^{1,2,‡}, Song Qu^{1,2,3,‡}, Minghai Zhou⁴, Lisa M Ryno^{1,2}, Shiyu Wang⁵, Matthew D Shoulders^{2,†}, Randal J Kaufman⁵, Corinne I Lasmézas⁴, Jeffery W Kelly^{1,2,6} & R Luke Wiseman^{1,3,*}

Abstract

The Unfolded Protein Response (UPR) indirectly regulates extracellular proteostasis through transcriptional remodeling of endoplasmic reticulum (ER) proteostasis pathways. This remodeling attenuates secretion of misfolded, aggregation-prone proteins during ER stress. Through these activities, the UPR has a critical role in preventing the extracellular protein aggregation associated with numerous human diseases. Here, we demonstrate that UPR activation also directly influences extracellular proteostasis through the upregulation and secretion of the ER HSP40 ERdj3/DNAJB11. Secreted ERdj3 binds misfolded proteins in the extracellular space, substoichiometrically inhibits protein aggregation, and attenuates proteotoxicity of disease-associated toxic prion protein. Moreover, ERdj3 can co-secrete with destabilized, aggregation-prone proteins in a stable complex under conditions where ER chaperoning capacity is overwhelmed, preemptively providing extracellular chaperoning of proteotoxic misfolded proteins that evade ER quality control. This regulated co-secretion of ERdj3 with misfolded clients directly links ER and extracellular proteostasis during conditions of ER stress. ERdj3 is, to our knowledge, the first metazoan chaperone whose secretion into the extracellular space is regulated by the UPR, revealing a new mechanism by which UPR activation regulates extracellular proteostasis.

Keywords ER stress; ERdj3; extracellular proteostasis; molecular chaperones; unfolded protein response

Subject Categories Membrane & Intracellular Transport; Protein Biosynthesis & Quality Control

DOI 10.15252/emboj.201488896 | Received 7 May 2014 | Revised 9 September 2014 | Accepted 23 September 2014 | Published online 31 October 2014

The EMBO Journal (2015) 34: 4–19

See also: **TM Buck & JL Brodsky** (January 2015)

Introduction

Imbalances in extracellular protein homeostasis (or proteostasis) and consequent protein aggregation are inextricably linked to degenerative phenotypes in over 30 human protein misfolding diseases, including Alzheimer's disease, Creutzfeldt–Jakob disease and the transthyretin (TTR) amyloidoses (Kelly, 1996; Rochet & Lansbury, 2000; Stefani & Dobson, 2003; Buxbaum, 2004; Haass & Selkoe, 2007). Compelling genetic and pharmacologic evidence supports a causal relationship between protein aggregation (including amyloidogenesis) and the degeneration of post-mitotic tissue in these disorders (Tanzi & Bertram, 2005; Aguzzi *et al.*, 2007; Gotz *et al.*, 2011; Coelho *et al.*, 2012). Primary determinants of extracellular proteostasis capacity include the spectrum and concentration of secreted proteostasis factors (e.g., chaperones) (Wyatt *et al.*, 2013) and the efficiency of protein folding and quality control in the endoplasmic reticulum (ER) (Wiseman *et al.*, 2007).

Extracellular proteostasis capacity is regulated by secreted proteins that prevent the formation of protein aggregates associated with disease. The best characterized secreted chaperones such as clusterin directly bind misfolded proteins in the extracellular environment and prevent their aggregation through an ATP-independent “holdase” mechanism (Wyatt *et al.*, 2012). Deletion of clusterin predisposes mice to aging-dependent progressive glomerulopathy (Rosenberg *et al.*, 2002) and increases Aβ(1–42) aggregation and deposition in mouse models of Alzheimer's disease (DeMattos *et al.*, 2004). Furthermore, genome-wide association studies implicate clusterin in the development of Alzheimer's disease (Harold *et al.*, 2009; Lambert *et al.*, 2009; Wijsman *et al.*, 2011). Small populations of some ER chaperones, such as the HSP70 BiP and the lectin calreticulin, can be trafficked to the plasma membrane, particularly under stress or during apoptosis (Martins *et al.*, 2010; Zhang *et al.*, 2010). Protein disulfide isomerases (PDIs) can also be secreted to promote extracellular disulfide exchange (Jordan & Gibbins, 2006; Hahn

1 Department of Molecular & Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA

2 Department of Chemistry, The Scripps Research Institute, La Jolla, CA, USA

3 Department of Chemical Physiology, The Scripps Research Institute, La Jolla, CA, USA

4 Department of Infectious Diseases, The Scripps Research Institute, Jupiter, FL, USA

5 Degenerative Disease Research Program, Sanford Burnham Medical Research Institute, La Jolla, CA, USA

6 The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, USA

*Corresponding author. Tel: +1 858 784 8820; Fax: +1 858 784 8891; E-mail: wiseman@scripps.edu

‡These authors contributed equally to this work

†Present address: Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA

et al, 2013). A role for these chaperones in extracellular proteostasis maintenance has not been demonstrated to date, rather their surface expression has been implicated in immunological signaling (Peters & Raghavan, 2011; Lee, 2014).

Extracellular proteostasis is also impacted by proteostasis in the ER, which is responsible for the folding and trafficking of the 1/3 of the human proteome that is targeted to the cellular secretory pathway (Fewell *et al*, 2001; Braakman & Bulleid, 2011). In the ER, nascent polypeptides interact with components of ER protein folding pathways to facilitate their folding into native three-dimensional conformations (Buck *et al*, 2007). Folded proteins are then packaged into vesicles at the ER membrane and trafficked to downstream compartments of the secretory pathway or the extracellular space. Proteins unable to attain native three-dimensional conformations in the ER are instead targeted to ER degradation pathways such as ER-associated degradation (ERAD) (Benyair *et al*, 2011). The partitioning of polypeptides between ER protein folding/trafficking and degradation pathways, also referred to as ER quality control, prevents the secretion of misfolded, aggregation-prone proteins (Powers *et al*, 2009; Araki & Nagata, 2011).

Despite the typical efficiency of ER quality control, exposure to genetic, environmental or aging-related stresses leads to increased protein misfolding within the ER lumen and imbalances in ER proteostasis. Such stresses can increase secretion of misfolding-prone proteins into the extracellular space, directly challenging extracellular proteostasis capacity and facilitating concentration-dependent protein aggregation into proteotoxic oligomeric conformations. As such, ER stress is pathologically associated with numerous extracellular protein aggregation diseases including the systemic amyloidoses and Alzheimer's disease (Teixeira *et al*, 2006; Kim *et al*, 2008).

To restore ER proteostasis following stress, cells activate the Unfolded Protein Response (UPR). The UPR consists of three integrated stress-responsive signaling pathways activated downstream of the ER stress-sensing proteins IRE1, ATF6, and PERK (Schroder & Kaufman, 2005; Walter & Ron, 2011). These stress sensors are activated by the accumulation of misfolded proteins within the ER lumen (a consequence of ER stress) (Bertolotti *et al*, 2000; Okamura *et al*, 2000; Shen *et al*, 2002). The activation of UPR signaling pathways results in the attenuation of new protein synthesis (Harding *et al*, 1999) and transcriptional remodeling of ER protein folding, trafficking, and degradation pathways (Lee *et al*, 2003; Yamamoto *et al*, 2007; Shoulders *et al*, 2013), thus enhancing ER proteostasis capacity and quality control. Through these mechanisms, UPR activation reduces accumulation of misfolded proteins in the ER and attenuates the aberrant secretion of aggregation-prone proteins into the extracellular space (Adachi *et al*, 2008; Shoulders *et al*, 2013).

In contrast, the functional impact of UPR signaling on extracellular proteostasis capacity remains poorly defined. Not only are the established secreted chaperones not transcriptional targets of the UPR, but clusterin secretion is attenuated during conditions of ER stress, indicating that clusterin secretion is not a protective mechanism to regulate extracellular proteostasis in response to pathologic ER insults (Nizard *et al*, 2007). Similarly, ER stress reduces secretion of ER proteostasis factors such as protein disulfide isomerase (PDI), suggesting reduced extracellular regulation of disulfide integrity during ER stress (Terada *et al*, 1995). Thus, we sought to study the functional role for UPR signaling in adapting extracellular proteostasis capacity during conditions of ER stress.

Here, we report that UPR activation regulates extracellular proteostasis *directly* through the secretion of the ER-targeted HSP40 co-chaperone ERdj3. While ERdj3 is established to function as an HSP40 co-chaperone for BiP within the ER HSP70 chaperoning pathway (Shen & Hendershot, 2005), we show that ERdj3 is also a UPR-induced secreted chaperone, whose extracellular levels increase both in response to ER stress and stress-independent activation of the UPR-associated transcription factor ATF6. Secreted ERdj3 binds to misfolded proteins in the extracellular space, prevents the aggregation of amyloidogenic A β ₁₋₄₀ at substoichiometric concentrations, and ameliorates the toxic effects of misfolded prion protein on neuronal cells. Furthermore, we demonstrate that ERdj3 can co-secrete with destabilized, misfolding-prone clients under conditions where the ER HSP70 chaperoning pathway is overwhelmed, preemptively chaperoning these misfolding-prone secreted proteins that evade ER quality control in the extracellular environment. Thus, the capacity for ERdj3 to function in both ER and extracellular proteostasis provides an unanticipated direct link between these two environments that is regulated by the UPR during conditions of ER stress.

Results

ER stress increases ERdj3 secretion

We sought to identify UPR-induced secreted chaperones that could increase extracellular proteostasis capacity in response to ER stress. We surveyed previously reported transcriptional and proteomic profiles (Lee *et al*, 2003; Wu *et al*, 2007; Yamamoto *et al*, 2007; Adachi *et al*, 2008; Shoulders *et al*, 2013) of UPR stress-responsive signaling to identify a UPR-induced gene(s) whose protein product: (1) is targeted to the ER by an N-terminal signaling sequence, (2) lacks an ER retention motif (e.g., KDEL) or a transmembrane domain (Dancourt & Barlowe, 2010), and (3) selectively binds destabilized, misfolded proteins (i.e., has chaperone activity). Through this analysis, we identified the HSP40 co-chaperone ERdj3 as a potential UPR-induced secreted chaperone that meets all of the above criteria.

ERdj3 is a well-established component of the *intracellular* ER proteostasis network and is transcriptionally upregulated by the UPR during ER stress (Shen & Hendershot, 2005). In the ER, ERdj3 binds to proteins in non-native conformations through an ATP-independent mechanism and directs these clients to the ER-localized, ATP-dependent HSP70 BiP chaperoning pathway, facilitating the proper folding of client proteins into folded three-dimensional conformations in the ER lumen (Shen & Hendershot, 2005; Jin *et al*, 2008, 2009; Marciniowski *et al*, 2011; Guo & Snapp, 2013). ERdj3 contains neither a C-terminal KDEL nor a transmembrane domain, implying that ERdj3 can efficiently traverse the secretory pathway. Consistent with this prediction, extracellular ERdj3 is implicated in neuronal development (Wong *et al*, 2010).

We evaluated whether ERdj3 is secreted from HEK293T cells overexpressing wild-type ERdj3 (ERdj3^{WT}). Overexpression of ERdj3^{WT} significantly increases extracellular ERdj3 protein levels in conditioned media, while only slightly increasing intracellular ERdj3 levels (Fig 1A). In contrast, overexpression of ERdj3 containing a C-terminal KDEL ER retention motif (ERdj3^{KDEL}) only slightly




Figure 1. ER stress increases ERdj3 secretion.

A Immunoblot of media and lysate collected from HEK293T cells overexpressing ERdj3^{WT} or ERdj3^{KDEL}. Fresh media was conditioned on cells for 24 h prior to harvest.

B qPCR analysis of *ERdj3* mRNA in HEK293T cells treated with or without thapsigargin (Tg; 6 h, 100 nM). Error bars represent the mean \pm 95% confidence interval as calculated in DataAssist 2.0 ($n = 3$).

C Representative immunoblot of lysates and media collected from HEK293T-Rex cells stably expressing non-silencing (NS) or *ERdj3* shRNA. Cells were treated with the indicated concentration of Tg in fresh media for 16 h.

D Quantification of the fold increase of ERdj3 in lysates and media collected from HEK293T-Rex cells treated with the indicated concentration of Tg in fresh media for 16 h as in (C). * $P < 0.05$; $n = 3$, mean \pm SEM.

E Representative autoradiogram of [³⁵S]-labeled ERdj3 in lysates and media collected from Huh7 cells incubated in the presence or the absence of Tg (1 μ M). The experimental paradigm for labeling is shown above.

F Quantification of fraction intracellular (dark gray) and extracellular (light gray) [³⁵S]-labeled ERdj3 following a 4 h chase relative to total [³⁵S]-labeled ERdj3 at 4 h (as shown in E). Error bars represent the standard error from biological replicates ($n = 3$).

G Quantification of total [³⁵S]-labeled ERdj3 in media collected from cells pretreated with vehicle or Tg, as shown in (E). The media [³⁵S]-labeled ERdj3 was measured by densitometry and is normalized to the amount of media [³⁵S]-labeled ERdj3 at 4 h from vehicle-treated cells. * P -value < 0.05 ; $n = 3$, mean \pm SEM.

H Representative immunoblot and quantification of sera collected at the indicated times from DBA/2J mice fed a high-fat (60% fat) diet after a 18 h fast. A schematic of the fasting/refeeding experimental setup is shown above. The quantification was normalized for each mouse to the amount of ERdj3 in the serum draw immediately prior the fast. * P -value < 0.05 ; $n = 6$, mean \pm SEM.

Source data are available online for this figure.

increases extracellular ERdj3 protein levels, while significantly increasing intracellular ERdj3 (Fig 1A). Furthermore, secretion of overexpressed ERdj3^{WT} is inhibited by the addition of the secretory trafficking inhibitor brefeldin A (Supplementary Fig S1A and B). These results strongly indicate that overexpressed ERdj3^{WT} is secreted through the canonical secretory pathway. Endogenous ERdj3 was also detected in conditioned media collected from a variety of human cell lines, including HepG2, Huh7, SH-SY5Y, and HeLa (Supplementary Fig S1C).

We confirmed the ER stress-dependent increase in *ERdj3* mRNA in HEK293T cells treated with the small molecule SERCA inhibitor thapsigargin (Tg)—a potent inducer of ER stress (Fig 1B). Upon Tg-induced ER stress, ERdj3 protein levels increased primarily in conditioned media and not intracellularly for HEK293T-Rex (Fig 1C and D). RNAi depletion of *ERdj3* reduced intracellular ERdj3 levels > 90% and completely ablated extracellular ERdj3 upon Tg treatment. Tg treatment also selectively increased extracellular, as opposed to intracellular, ERdj3 from Huh7 cells (Supplementary Fig S1D). In stark contrast to ERdj3, BiP and HYOU1, two abundantly expressed, UPR-induced, ER chaperones, were not detected in the conditioned media (Fig 1C), reflecting the presence of ER retention motifs on these proteins. These results are consistent with previous results showing that negligible BiP is secreted to the extracellular space (Munro & Pelham, 1987; Yamamoto *et al*, 2003; Kern *et al*, 2009). Rather, BiP that evades the KDEL receptor is typically still retained at the cellular membrane (Wang *et al*, 2009; Zhang *et al*, 2010), as is common for other canonical ER-localized chaperones, particularly under apoptotic conditions (Jordan & Gibbins, 2006; Martins *et al*, 2010; Lee, 2014). HYOU1, the ER resident Hsp110 that both serves as a nucleotide exchange factor for BiP and displays its own chaperone function (Andreasson *et al*, 2010; Behnke & Hendershot, 2014), has not been implicated in either secretion or presentation at the cellular membrane. Alternatively, intracellular levels of BiP and HYOU1 were significantly increased upon Tg treatment. These data indicate that increased extracellular ERdj3 levels result from constitutive secretion and not from leakage of ER proteins into the extracellular space, as has been proposed for other ER chaperones (Booth & Koch, 1989).

To quantify ERdj3 secretion in the presence or the absence of ER stress, Huh7 cells were pretreated with Tg or vehicle, metabolically pulse labeled with [³⁵S]-Cys/Met, and then incubated in non-radioactive chase media. At the indicated time, [³⁵S]-labeled ERdj3 was immunopurified from both denatured lysates and media and analyzed by autoradiography (Fig 1E). We found that ~50% of newly synthesized ERdj3 was secreted from Huh7 cells within 4 h, in the presence or the absence of Tg (Fig 1E and F), consistent with ERdj3 being highly secreted from hepatic cells (Supplementary Fig S1C). Tg significantly increased the absolute amount of ERdj3 secreted relative to vehicle-treated controls (Fig 1G), similar to what was observed by immunoblotting (Supplementary Fig S1D). These results further demonstrate that the ERdj3 secretion is not a consequence of cell death or “leaky” release of ER proteins into the cellular media. These results also distinguish ERdj3 from other ER chaperones such as BiP or calreticulin, for which only a minor fraction of newly synthesized protein is released into the extracellular space, even during stress (Dorner *et al*, 1987; Lodish & Kong, 1990; Peters & Raghavan, 2011). Rather, the efficiency and selectivity of ERdj3 secretion

indicates that its secretion is regulated by the canonical secretory pathway.

We next evaluated whether ER stress increases ERdj3 serum levels in mice. In the absence of stress, ERdj3 has a serum concentration of 23 ± 5 nM (Supplementary Fig S1E). Mice subjected to an 18 h fast followed by refeeding on a high-fat diet, which rapidly induces hepatic ER stress (Oyadomari *et al*, 2008), show a significant twofold increase in serum ERdj3 levels (Fig 1H). ERdj3 serum levels also significantly increased following 7 days on a high-fructose diet (Supplementary Fig S1F and G), which also induces ER stress in hepatic cells (Wang *et al*, 2012), as indicated by increased BiP, Grp94, and phosphorylated eIF2 α in hepatic lysates (Supplementary Fig S1H). These results demonstrate that increased ERdj3 serum levels in mice correlate with hepatic ER stress, strongly indicating that hepatic ER stress increases ERdj3 secretion *in vivo*.

Stress-independent activation of the UPR-associated transcription factor ATF6 increases ERdj3 secretion

The ER stress-dependent increase in secreted ERdj3 indicates that *ERdj3* is induced by the UPR. Consistent with this prediction, stress-independent activation of either of the primary UPR-associated transcription factors, ATF6 or XBP1s, increases *ERdj3* transcription (Sriburi *et al*, 2004; Shoulders *et al*, 2013). To identify the specific UPR transcription factor(s) responsible for the stress-responsive increase in ERdj3 secretion, we employed HEK293T-Rex cells expressing tetracycline (tet)-inducible XBP1s and a constitutively expressed fusion protein consisting of destabilized bacterial DHFR fused N-terminally to an active ATF6 transcription factor sequence (referred to as HEK293^{DAX}) (Shoulders *et al*, 2013). In these cells, the addition of the DHFR pharmacologic chaperone trimethoprim (TMP, which stabilizes the DHFR:ATF6 fusion protein) activates the ATF6 transcriptional program, while the addition of doxycycline (dox) activates the XBP1s transcriptional program. These HEK293^{DAX} cells allow for the activation of ATF6 and/or XBP1s in the same cell in the absence of ER stress (Shoulders *et al*, 2013). In HEK293^{DAX} cells, *ERdj3* mRNA is increased by stress-independent activation of ATF6 and/or XBP1s to similar levels observed with Tg (Supplementary Fig S2A), as previously reported (Shoulders *et al*, 2013). Furthermore, [³⁵S] metabolic labeling demonstrates that ATF6 and/or XBP1s activation increases ERdj3 protein synthesis to similar extents (Supplementary Fig S2B). Hence, we expected that stress-independent activation of either ATF6 or XBP1s would enhance secretion of ERdj3.

Surprisingly, we found that the activation of ATF6, but not XBP1s, selectively increased ERdj3 levels in the media relative to lysates (Fig 2A). Co-activation of ATF6 and XBP1s resulted in a similar amount of secreted ERdj3 to that observed with ATF6 activation alone. We did not identify immunodetectable levels of other abundant ER chaperones induced by ATF6, such as BiP, in conditioned media, further indicating that ATF6 selectively increases ERdj3 secretion (Fig 2A). Longer conditioning under ATF6 activation (48 h) also failed to lead to immunodetectable BiP in conditioned media (Supplementary Fig S2C). Importantly, TMP addition to control cells expressing destabilized DHFR fused N-terminally to YFP (Shoulders *et al*, 2013) did not increase extracellular ERdj3 (Supplementary Fig S2D), demonstrating that stress-independent




Figure 2. ERdj3 is efficiently secreted from cells following stress-independent activation of the UPR-associated transcription factor ATF6.

- A** Immunoblot of lysates and media collected from HEK293^{DAX} cells following 16 h of activation of XBP1s (by 1 μ g/ml dox) and/or ATF6 (by 10 μ M TMP), as indicated (Shoulders *et al.*, 2013). Immunoblots of the ATF6 target protein BiP (reactive with the KDEL antibody) and the XBP1s target Sec24D confirm the small-molecule activation of these transcription factors.
- B** Representative autoradiogram of [³⁵S]-labeled ERdj3 immunopurified from lysates and media collected from HEK293^{DAX} cells following preactivation of XBP1s (by 1 μ g/ml dox) and/or ATF6 (by 10 μ M TMP) (Shoulders *et al.*, 2013). The experimental protocol is shown above.
- C** Quantification of relative amounts of [³⁵S]-labeled ERdj3 in media at 8 h collected from cells treated as shown in (B) ($n = 3$). The media [³⁵S]-labeled ERdj3 was measured by densitometry and is normalized to the amount of media [³⁵S]-labeled ERdj3 at 8 h from vehicle-treated cells.
- D, E** Quantification of the fraction ERdj3 secreted (D) and the fraction ERdj3 remaining (E) from autoradiograms as shown in (B). The fractions of ERdj3 secreted/ERdj3 remaining were calculated by normalizing the recovered [³⁵S]-labeled ERdj3 signal in the media and in the lysates at $t = 4$ or 8 h to the total amount of [³⁵S]-labeled ERdj3 signal in the media and lysates at $t = 0$ h.

Data information: Error bars represent the standard error from biological replicates ($n = 3$). * P -value < 0.05; ** P -value < 0.01; *** P -value < 0.001 as compared to the vehicle-treated condition.

Source data are available online for this figure.

activation of the ATF6 transcriptional program is required for the increase in secreted ERdj3 observed in TMP-treated HEK293^{DAX} cells. Overexpression of ATF6, but not XBP1s, similarly increased secreted ERdj3 in HepG2 cells (Supplementary Fig S2E).

We further characterized the ATF6-dependent increase in ERdj3 secretion using a [³⁵S] metabolic pulse-chase approach. ATF6 preactivation increased the extracellular concentration of newly synthesized ERdj3 fourfold relative to vehicle-treated cells, with nearly 40% of [³⁵S] labeled ERdj3 being secreted following a 4 h incubation in non-radioactive chase media (Fig 2B–D). Despite an increase in ERdj3 synthesis (Supplementary Fig S2B), XBP1s preactivation reduced the fraction of newly synthesized ERdj3 in media, relative

to the vehicle treatment (Fig 2D). This decrease in ERdj3 secretion is attributed to an increase in ERdj3 degradation, with ~40% of newly synthesized ERdj3 being degraded after 4 h in cells following XBP1s preactivation (Fig 2E). ATF6 and XBP1s co-activation demonstrated a similar increase in ERdj3 secretion to that observed with ATF6 preactivation alone, demonstrating that ATF6 activation prevents the increased ERdj3 degradation observed upon XBP1s activation (Fig 2B–E). Collectively, these results show that ERdj3 secretion is increased by stress-independent preactivation of the UPR-associated transcription factor ATF6, directly implicating protective UPR signaling in the regulation of the extracellular ERdj3 concentration.

Secreted ERdj3 increases extracellular proteostasis capacity

To evaluate whether ERdj3 secretion is critical for the maintenance of intracellular ER proteostasis, we overexpressed either ERdj3^{WT} or the non-secreted ERdj3^{KDEL} and then measured expression of UPR target genes and cellular viability, both in the absence and the presence of Tg-induced ER stress (Supplementary Fig S3A and B). Despite the known role of ERdj3 in folding and degradation of specific clients (Shen & Hendershot, 2005; Hoshino *et al*, 2007; Jin *et al*, 2008; Buck *et al*, 2010; Tan *et al*, 2014), ERdj3 retention does not significantly impair global ER proteostasis maintenance in the absence or the presence of ER stress.

Alternatively, ERdj3 secretion during ER stress could enhance extracellular proteostasis capacity, by binding to misfolded proteins. To test the capacity for secreted ERdj3 to bind misfolded proteins, media collected from cells overexpressing ERdj3^{WT} or ERdj3^{H53Q}—an ERdj3 mutant deficient in delivering protein clients to BiP (Shen & Hendershot, 2005)—was incubated with sepharose resin conjugated to natively folded or denatured RNase A (Petrova *et al*, 2008).

After washing the beads, proteins bound to resin were eluted and analyzed by immunoblotting (Fig 3A). ERdj3^{WT} selectively associates with denatured RNase A, as compared to natively folded RNase A, indicating that secreted ERdj3 selectively binds misfolded protein clients in the extracellular environment. The capacity for ERdj3^{H53Q} to similarly associate with denatured RNase A resin indicates that secreted ERdj3 interacts with denatured substrates through a mechanism largely independent of its intracellular role as an HSP40 co-chaperone that delivers misfolded substrates to BiP for ATP-dependent chaperoning.

We next prepared recombinant ERdj3 (^RERdj3) in *E. coli* to assess the capacity of ERdj3 to inhibit protein aggregation. We confirmed that, despite the lack of the sole N-glycan present in mammalian ERdj3, ^RERdj3 is a folded protein as assessed by far-UV circular dichroism (Supplementary Fig S3C), is functional in that it stimulates recombinant BiP ATPase activity (Supplementary Fig S3D), and maintains the capacity to selectively bind denatured RNase A resin (Supplementary Fig S3E). We monitored the aggregation of the amyloidogenic Aβ₁₋₄₀ peptide (10 μM) associated with Alzheimer's




Figure 3. Secreted ERdj3 inhibits extracellular protein aggregation.

- A** Immunoblot of conditioned media collected from HEK293T cells transiently transfected with ERdj3^{WT} or ERdj3^{H53Q} and incubated with an affinity resin consisting of native (N) or guanidinium hydrochloride (GdnHCl)-denatured (D) RNase A covalently coupled to sepharose resin. Resin was incubated with media for 2 h at ambient temperature, followed by washing and then elution in Laemmli reducing buffer.
- B** Plot showing the time-dependent increase in ThioT fluorescence (ex: 440 nm, em: 485 nm) of Aβ₁₋₄₀ incubated (10 μM, 37°C, pH 7.2) with regular agitation in the presence or the absence (black) of recombinant ERdj3 (^RERdj3). The ^RERdj3 concentrations and molar ratios of ^RERdj3 to Aβ₁₋₄₀ are as follows: violet: 1.5 nM, 1:6,561; light blue: 4.6 nM, 1:2,187; dark blue: 14 nM, 1:729; dark green: 41 nM, 1:243; light green: 120 nM, 1:81; yellow: 370 nM, 1:27; orange: 1.1 μM, 1:9; red: 3.3 μM, 1:3; or maroon: 10 μM, 1:1. All traces represent the average of three replicates.
- C** Plot showing the time-dependent increase in ThioT fluorescence of Aβ₁₋₄₀ incubated (10 μM, 37°C, pH 7.2) with regular agitation in the presence or the absence of BSA (14 μg/ml) or ^RERdj3 (14 μg/ml; 370 nM, ^RERdj3: Aβ = 1:27). All traces represent the average of three replicates.
- D** Immunoblot of Aβ₁₋₄₀ incubated (10 μM, 37°C, pH 7.2) with regular agitation for 90 h in the presence or the absence of ^RERdj3 (14 μg/ml; 370 nM, ^RERdj3: Aβ₁₋₄₀ = 1:27) or BSA (14 μg/ml). The reaction solution in the well was collected (Nonadhered) and separated into soluble and insoluble fractions by centrifugation. These samples, as well as the washed wells of the plate (Adhered), were denatured in 8 M GdnHCl with sonication and analyzed by SDS-PAGE/immunoblotting.

Source data are available online for this figure.

disease using thioflavin T (ThioT) fluorescence in the presence of increasing R ERdj3 concentrations. ThioT fluorescence sharply increases upon binding to amyloid fibers (Du *et al*, 2011). R ERdj3 completely inhibited the aggregation of A β_{1-40} at concentrations above 370 nM (an ERdj3: A β_{1-40} ratio of 1:27) (Fig 3B). The control serum protein bovine serum albumin (BSA), a protein known to modestly inhibit A β aggregation (Bohrmann *et al*, 1999; Mилоjevic *et al*, 2007, 2009; Reyes Barcelo *et al*, 2009), did not dramatically influence A β_{1-40} aggregation at an equivalent mass concentration (Fig 3C). The ERdj3-dependent decrease in A β_{1-40} aggregation was similarly observed by differential centrifugation, with substoichiometric levels of R ERdj3 significantly reducing the population of A β_{1-40} in the pelleted aggregates following a 96 h incubation (Fig 3D). Denaturation of R ERdj3 by boiling in the presence of dithiothreitol attenuated the ERdj3-dependent reduction in A β_{1-40} aggregation, demonstrating that the reduction in protein aggregation afforded by R ERdj3 requires a native ERdj3 structure (Supplementary Fig S3F).

We next tested whether secreted ERdj3 could impact the cellular phenotype associated with another misfolded protein, the toxic prion protein (TPrP) (Zhou *et al*, 2012). TPrP is a monomeric, misfolded prion conformer that upon addition to neuronal cells recapitulates the cytoplasmic vacuole formation characteristic of prion diseases in patients (Will *et al*, 1996). TPrP induces this phenotype

at 600 ng/ml, similar to the extracellular concentrations of prion protein associated with prion diseases in patients (Meyne *et al*, 2009), providing a highly sensitive phenotypic assay for quantifying the protective effects of secreted ERdj3. We treated PK1 mouse neuroblastoma cells with TPrP for 3 days in the presence of media conditioned on HEK293T-Rex cells overexpressing ERdj3^{WT} (Supplementary Fig S4A) and evaluated the extent of vacuole formation (Fig 4A). Strikingly, media conditioned on cells overexpressing ERdj3^{WT} ([ERdj3^{WT}]_{media} = 100–400 nM) significantly attenuated TPrP-induced vacuole formation in PK1 cells (Fig 4B and C), as compared to treatment with control conditioned media ([endogenous ERdj3]_{media} = 2–4 nM), demonstrating that secreted ERdj3^{WT} protects neuroblastoma cells against TPrP toxicity. Alternatively, TPrP incubated with conditioned media prepared on HEK293T-Rex cells RNAi-depleted of *ERdj3* significantly aggravated vacuole formation in TPrP-treated PK1 cells, as compared to conditioned media prepared from HEK293T-Rex cells expressing non-silencing shRNA ([endogenous ERdj3]_{media} = 2–4 nM) (Supplementary Fig S4A–C). This indicates that, even the low level of endogenous ERdj3 secreted from HEK293T-Rex in the absence of stress, which is about 10–20% of the measured physiological concentration of ERdj3 in mouse serum (23 nM; Supplementary Fig S1E), increases extracellular proteostasis capacity and protects cells from TPrP proteotoxicity.




Figure 4. Secreted ERdj3 attenuates vacuole formation induced by toxic prion protein in mammalian cells.

A Schematic illustrating the treatment of PK1 cells with ERdj3-conditioned media. HEK293T-Rex (Control) and HEK293T-Rex cells stably overexpressing tet-inducible ERdj3^{WT} on poly-D-lysine-coated plates were treated with dox (1 μ g/ml) overnight to induce ERdj3^{WT} expression. The media was replaced with fresh OptiMEM I + 5% FBS, which was conditioned for 30 h, sterile-filtered, concentrated 5 \times against a 3 kD MWCO membrane, and diluted 1:1.5 with fresh OptiMEM I + 5% FBS. PK1 cells were plated in OptiMEM I + 5% FBS and after 24 h were treated with conditioned media and TPrP (600 ng/ml) for 3 days.

B Representative images under 136 \times magnification of PK1 cells incubated with control conditioned media collected from HEK293T-Rex or conditioned media prepared from HEK293T-Rex cells overexpressing ERdj3^{WT} in the presence or the absence of TPrP (600 ng/ml), as described in (A). Arrows indicate representative cells containing vacuoles. Insets show 544 \times magnification of a typical region of the image.

C Quantification of vacuole formation from images as shown in (B). Equal area images comprising \sim 1,200 cells per well were counted for each sample. Counting of cells and of cells with identifiable vacuoles was done using the Fiji image processing package (Schindelin *et al*, 2012). ****P*-value < 0.001 (*n* = 3); mean \pm SEM.

ERdj3 is co-secreted in complex with secreted destabilized mutant proteins

Since ERdj3 binds misfolded, non-native protein conformations in the ER lumen (Shen & Hendershot, 2005), we wondered whether ERdj3 could be co-secreted into the extracellular environment in complex with non-natively folded proteins. To test this prediction, we employed the destabilized, misfolding-prone A25T transthyretin

mutant (TTR^{A25T}), a highly amyloidogenic, poorly secreted, disease-associated TTR variant (Sekijima *et al*, 2003, 2005), previously shown to interact with ERdj3 intracellularly (Shoulders *et al*, 2013). We immunopurified TTR from conditioned media collected from either a mixed population of HEK293T cells individually overexpressing FLAG-tagged TTR^{A25T} (FTTTR^{A25T}) or ERdj3^{WT} (Fig 5A, “co-incubation”; a condition where FTTTR^{A25T} and ERdj3^{WT} can only interact in the media) or cells co-overexpressing FTTTR^{A25T} and




Figure 5. ERdj3 is co-secreted with destabilized proteins through the secretory pathway.

- A** Schematic describing the co-incubation and co-expression experiments used to demonstrate ERdj3 co-secretion with destabilized TTR. For co-incubation, HEK293T cells overexpressing FLAG-tag TTR (FTTTR) variants were seeded with an equal number of cells overexpressing ERdj3^{WT}. For co-expression experiments, HEK293T cells are transfected with both FTTTR and ERdj3^{WT}. FTTTR was immunoprecipitated with M2 anti-FLAG beads from media conditioned overnight on the cells, eluted, and separated by SDS-PAGE for immunoblotting.
- B** Immunoblot of M2 anti-FLAG immunoprecipitations from the conditioned media collected from HEK293T cells overexpressing FTTTR^{WT}, FTTTR^{A25T}, and/or ERdj3^{WT} either as a co-incubation or co-expression experiment as shown in (A). Beads were washed in RIPA buffer prior to elution. Media inputs (1:400) are shown as a control.
- C** Immunoblot of M2 anti-FLAG immunoprecipitations from media collected from HEK293T cells overexpressing ERdj3^{WT} and FTTTR variants as indicated. Media inputs (1:400) are shown as a control.
- D** Immunoblot of M2 anti-FLAG immunoprecipitations from conditioned media of HEK293T cells overexpressing FTTTR^{A25T} and ERdj3^{WT} in the presence of the indicated concentrations of Tafamidis, a kinetic stabilizer of TTR tetramers. Media inputs (1:400) are shown as a control.
- E** Immunoblot of 6E10 anti-APP immunoprecipitations from the conditioned media of CHO cells or CHO-derived APP₇₅₁-expressing (7WD10) cells overexpressing ERdj3^{WT} as indicated. Cells were replated together as indicated 24 h after transfection at equal stoichiometry, and media conditioned for 36 h. In this case, ERdj3^{WT}-transfected CHO cells replated with mock-transfected 7WD10 cells serves as the co-incubation condition, while mock-transfected CHO cells replated with ERdj3^{WT}-transfected 7WD10 cells comprise the co-expression condition. Media inputs (1:150) are shown as a control.

Source data are available online for this figure.

ERdj3^{WT} (Fig 5A; “co-expression”; a condition where ^{FT}TTR^{A25T} and ERdj3^{WT} can interact both in the secretory pathway and in the media). Following stringent washing of the immunisolated secreted TTR in high-detergent RIPA buffer, we eluted and quantified the amount of ERdj3 associated with ^{FT}TTR^{A25T} by immunoblotting. Despite similar media levels of both ERdj3^{WT} and ^{FT}TTR^{A25T} in the distinct experimental paradigms, ERdj3 efficiently co-immunopurifies with ^{FT}TTR^{A25T} only in media collected from cells co-overexpressing both ERdj3^{WT} and ^{FT}TTR^{A25T} (Fig 5B). ERdj3 does not co-immunopurify with TTR in media collected from cells co-overexpressing stable, FLAG-tagged wild-type TTR (^{FT}TTR^{WT}) and ERdj3^{WT}, indicating that ERdj3–TTR complex formation is specific to destabilized TTR (Fig 5B). We observe a modest amount of ERdj3 associated with ^{FT}TTR^{A25T}, but not ^{FT}TTR^{WT}, in the “co-incubation” condition when the immunisolate is washed less stringently with mild detergent, indicating that free ERdj3 and ^{FT}TTR^{A25T} do interact extracellularly, but more weakly than in the co-secreted complex (Supplementary Fig S5A). We obtained similar results in HepG2 and SH-SY5Y cells, where we observed that endogenously secreted ERdj3 selectively co-immunopurifies with overexpressed ^{FT}TTR^{A25T}, but not ^{FT}TTR^{WT} (Supplementary Fig S5B–D). Interestingly, we do not recover all of the total secreted ERdj3 in these experiments (compare ^{FT}TTR^{A25T} immunopurifications and inputs in Supplementary Fig S5B and D), suggesting that even under conditions where a destabilized misfolding-prone protein is overexpressed, ERdj3 can still be secreted as a free protein available for the binding of misfolded proteins in the extracellular environment. Critically, ERdj3^{WT} overexpression does not promote the secretion of the highly destabilized, non-secreted ^{FT}TTR^{D18G} variant (Hammarstrom *et al*, 2003; Sato *et al*, 2007) (Fig 5C), despite a strong intracellular interaction between ERdj3 and ^{FT}TTR^{D18G} (Supplementary Fig S5E). This result indicates that secretion in complex with ERdj3 is not a mechanism for a misfolding-prone protein to evade ER quality control.

Interestingly, ERdj3^{WT} co-secretion with ^{FT}M-TTR, a stable, secreted monomeric TTR double mutant unable to form native TTR homotetramers (Jiang *et al*, 2001; Sekijima *et al*, 2005) is lower than with ^{FT}TTR^{A25T} (Fig 5C), indicating that secretion of ERdj3–TTR complexes requires a destabilized TTR. We further explored the dependence of ERdj3–TTR co-secretion on TTR stability using the small molecule TTR kinetic stabilizer Tafamidis (Bulawa *et al*, 2012). Tafamidis binds to and stabilizes the native TTR tetramer in the ER lumen, acting as a pharmacologic chaperone (Shoulders *et al*, 2013). The addition of Tafamidis to cells co-overexpressing ^{FT}TTR^{A25T} and ERdj3^{WT} increased ^{FT}TTR^{A25T} secretion while eliminating the co-immunopurification of ERdj3^{WT} with ^{FT}TTR^{A25T} in conditioned media (Fig 5D). These results demonstrate that ERdj3 co-secretion requires client destabilization.

We next evaluated whether ERdj3 could be co-secreted in complex with other destabilized, secreted proteins. Motivated by the substoichiometric inhibition of Aβ_{1–40} aggregation by ERdj3, we measured ERdj3 co-secretion in a stable CHO-derived cell line (7WD10) that secretes a spectrum of APP₇₅₁-associated cleavage products, including Aβ_{1–40} (Xia *et al*, 1997). We collected conditioned media from plates with either a mixed population of CHO cells overexpressing GFP and 7WD10 cells overexpressing ERdj3^{WT} (mimicking “co-expression”) or a mixed population of CHO cells overexpressing ERdj3^{WT} and of 7WD10 cells, which produce APP, also overexpressing GFP (mimicking “co-incubation”). Aβ-containing species were

then immunoprecipitated from the conditioned media with the 6E10 antibody, which recognizes an epitope within the Aβ fragment, and eluates were analyzed by immunoblotting. ERdj3 only co-immunopurifies with APP fragments from media conditioned on 7WD10 cells overexpressing ERdj3^{WT} (i.e., “co-expression” of ERdj3^{WT} and APP) (Fig 5E), demonstrating that the secretion of ERdj3–client complexes is a mechanism not limited to destabilized TTRs.

Other secreted chaperones, most prominently clusterin, also have the capacity to bind misfolded proteins in the extracellular space and prevent extracellular protein aggregation into proteotoxic conformations (Wyatt *et al*, 2013). Interestingly, while the steady-state plasma concentration of clusterin is reported to be between 500 nM and 2 μM (Schrijvers *et al*, 2011; Silajdzic *et al*, 2012; van Dijk *et al*, 2013), about 20- to 80-fold higher than we report for ERdj3, it is not induced by the UPR; rather, UPR induction reduces clusterin secretion (Nizard *et al*, 2007). This suggests that ERdj3 has a unique role in regulating extracellular proteostasis in response to ER stress. Since clusterin is not known to contribute to ER proteostasis, we explored whether clusterin can co-secrete from the ER with destabilized proteins using a C-terminally HA-tagged clusterin (CLU^{3xHA}) and ^{FT}TTR^{A25T}. While we detected abundant clusterin from ^{FT}TTR^{A25T} immunisolations in the co-expression condition, as compared to the co-incubation condition, we also observed a sharp increase in secreted ^{FT}TTR^{A25T} upon clusterin co-overexpression (Supplementary Fig S5F). Furthermore, when we co-express clusterin with the non-secreted ^{FT}TTR^{D18G} mutant, we detected a significant increase of ^{FT}TTR^{D18G} secretion (Supplementary Fig S5G), an effect not seen with ERdj3 or explainable by variation in ^{FT}TTR^{D18G} expression (Supplementary Fig S5H). These results suggest that formation of clusterin–client complexes can allow clients to evade ER quality control, clearly distinguishing the clusterin co-secretion mechanism from that observed with the UPR-regulated secreted chaperone ERdj3.

ERdj3–client co-secretion is regulated by ER proteostasis capacity

The differential capacity of ERdj3 and clusterin to be co-secreted with ER clients could represent the differential involvement of these secreted chaperones in ER proteostasis maintenance. ERdj3 functions intracellularly in a network with the ER HSP70 chaperone BiP, delivering misfolded proteins to BiP for ATP-dependent chaperoning. Alternatively, clusterin is not known to have functional interactions with any ER proteostasis pathway component. Thus, we predicted that the co-secretion of ERdj3 with substrate could be influenced by the activity and capacity of ER proteostasis factors such as BiP.

We tested whether ER stress influences the amount of endogenous ERdj3 co-secreting with ^{FT}TTR^{A25T}. In the absence of stress, modest amounts of endogenous ERdj3 co-immunopurified with ^{FT}TTR^{A25T} in conditioned media collected from HEK293T-Rex cells overexpressing ^{FT}TTR^{A25T} (Supplementary Fig S6A). Despite reducing ^{FT}TTR^{A25T} secretion through ER stress-dependent UPR activation (Shoulders *et al*, 2013), pretreatment with Tg increased the relative recovery of secreted ERdj3 in ^{FT}TTR^{A25T} immunopurifications (Supplementary Fig S6A and B). This ER stress-induced change in the association between ERdj3 and its clients suggests that ER proteostasis network components are involved in regulating ERdj3 co-secretion.

Because intracellular ERdj3 delivers destabilized proteins to BiP for ATP-dependent chaperoning, co-secretion of ERdj3 with destabilized mutant proteins could reflect a relative deficit in the ER

chaperone capacity in the ER lumen (e.g., BiP levels). To evaluate the role of the ER chaperone environment on ERdj3–client co-secretion, we initially employed our HEK293^{DAX} cell line that allows ligand-regulated activation of the UPR transcription factor ATF6 (Shoulders *et al*, 2013). ATF6 increases the expression of BiP and numerous BiP co-chaperones including ERdj3 and HYOU1 (Shoulders *et al*, 2013). Activation of ATF6 significantly reduced the relative recovery of

secreted ERdj3 (normalized to recovered TTR) in FLAG immunopurifications of media collected from HEK293^{DAX} cells overexpressing ^{FT}TTR^{A25T} and ERdj3^{WT} (Fig 6A and B). Interestingly, ATF6 activation did not influence the ERdj3 recovery in media when ^{FT}TTR^{A25T} was co-overexpressed with ERdj3^{H53Q}—an ERdj3 mutant deficient in delivering protein clients to BiP (Shen & Hendershot, 2005)—suggesting that BiP activity mediates the suppression of




Figure 6. ERdj3–client protein complexes are co-secreted when BiP activity is limiting.

- A Representative immunoblot of M2 anti-FLAG immunopurification of media conditioned for 24 h on HEK293^{DAX} cells co-overexpressing ^{FT}TTR^{A25T} and ERdj3^{WT} or ERdj3^{H53Q}. Media contained vehicle or trimethoprim (TMP, 10 μM, 16 h; activates ATF6), as indicated. Media inputs (1:400) are shown as a control. Lysates from these cells are also shown to confirm the increase of the ATF6 target proteins BiP and GRP94 in cells following TMP-dependent activation of ATF6.
- B Bar graph depicting quantification of the change in the amount of ERdj3 co-immunoprecipitating with TTR^{A25T} following activation of ATF6 as in (A). The ERdj3/TTR ratio is normalized to the ratio in the absence of ATF6 activation. **P*-value < 0.05; *n* = 3, mean ± SEM.
- C Representative immunoblot of M2 anti-FLAG immunopurification of media conditioned for 24 h on HEK293T cells co-overexpressing ^{FT}TTR^{A25T}, ERdj3^{WT}, ERdj3^{H53Q}, and/or BiP as indicated. Media inputs (1:400) are shown as a control. Lysates from these cells are also shown to confirm the increase of BiP afforded by overexpression.
- D Quantification of immunoblots of M2 anti-FLAG immunopurification of media collected from cells co-overexpressing either ERdj3^{WT} or ERdj3^{H53Q}, ^{FT}TTR^{A25T}, and BiP as in (C). The ERdj3/TTR ratio is normalized to the ratio in the absence of BiP overexpression. ***P*-value < 0.01; *n* = 5, mean ± SEM.
- E Immunoblot of 6E10 anti-APP immunopurifications from the conditioned media of CHO-derived APP₇₅₁-expressing (7WD10) cells overexpressing ERdj3^{WT}, ERdj3^{H53Q}, and BiP as indicated. Media inputs (1:100) are shown as a control. Lysates from these cells are also shown to confirm the increase of BiP afforded by overexpression.

Source data are available online for this figure.

ERdj3^{WT-FTTTR^{A25T}} complex secretion afforded by ATF6 activation. We directly tested the impact of BiP activity on ERdj3-^{FTTTR^{A25T}} co-secretion in HEK293T cells overexpressing ^{FTTTR^{A25T}}, ERdj3 (ERdj3^{WT} or ERdj3^{H53Q}), and BiP. BiP overexpression significantly reduces the relative recovery of secreted ERdj3^{WT} in ^{FTTTR^{A25T}} immunoprecipitations in conditioned media, but does not reduce the relative recovery of secreted ERdj3^{H53Q} (Fig 6C and D). This indicates that a functional ERdj3-BiP interaction is necessary for the reduction in ERdj3^{WT-FTTTR^{A25T}} complex secretion induced by BiP overexpression. Despite a robust interaction between BiP and intracellular ^{FTTTR^{A25T}}, BiP does not appear in extracellular ^{FTTTR^{A25T}} immunoprecipitations, consistent with our inability to observe extracellular BiP and supporting our model whereby extracellular ERdj3 functions independent of BiP (Supplementary Fig S6C). Co-overexpression of BiP similarly reduced co-secretion of ERdj3^{WT} with APP cleavage products, indicating that this effect is not limited to destabilized TTRs (Fig 6E). By contrast, and consistent with its lack of interaction with ER proteostasis pathways, the relative recovery of clusterin in ^{FTTTR^{A25T}} immunoprecipitations is insensitive to BiP overexpression, indicating that clusterin co-secretion with ^{FTTTR^{A25T}} is not influenced by BiP activity (Supplementary Fig S6D and E). These results are consistent with a model wherein if ERdj3 is unable to deliver a misfolded client protein to BiP, ERdj3 and the client protein will remain in complex and be secreted to the extracellular space.

Discussion

Protein synthesis is necessarily an intracellular process. Hence, extracellular metazoan environments such as the blood rely on cellular protein secretion to define extracellular protein concentrations and regulate the integrity of the secreted proteome. The presence of misfolding-prone proteins in the ER directly threatens this environment, as imbalances in ER proteostasis can impair the capacity for ER quality control pathways to prevent secretion of misfolded, aggregation-prone client proteins that in turn challenge the integrity of the extracellular proteome (Hetz & Mollereau, 2014). The UPR *indirectly* regulates extracellular proteostasis by attenuating the secretion of misfolded protein conformations that can both accumulate during and induce ER stress. Here, we demonstrate a *direct* role for the UPR in regulating extracellular proteostasis through the increased transcription and secretion of ERdj3. The capacity for UPR activation to influence extracellular proteostasis through ERdj3 secretion links protein misfolding in the secretory pathway to extracellular proteostasis, revealing a new mechanism by which cells coordinate intra- and extracellular environments in response to pathologic insults that induce ER stress (Fig 7).

In its role as a traditional HSP40 co-chaperone to BiP, ERdj3 can influence the trafficking of ER client proteins and is exploited for pathogenic toxin internalization (Yu & Haslam, 2005; Massey *et al*, 2011) and viral infection (Wen & Damania, 2010; Goodwin *et al*, 2011) (Fig 7). However, we find that at least half of newly synthesized ERdj3 is secreted. Secreted ERdj3 has the capacity to bind misfolded proteins and prevent their extracellular aggregation and proteotoxicity, suggesting that UPR-dependent increases in ERdj3 secretion offer a new potential mechanism to protect the local extracellular environment from toxic protein conformations that can be secreted during ER stress (Fig 7). Interestingly, ERdj3 also can also influence




Figure 7. ERdj3 secretion links ER and extracellular proteostasis environments during conditions of ER stress.

In response to ER stress, newly synthesized ERdj3 binds misfolded ER client proteins and delivers them to BiP for chaperoning in the Hsp70 cycle. When free BiP becomes limiting, or if repeated BiP cycling cannot productively deplete the levels of the misfolded client, the stable ERdj3-client complex is co-secreted to the extracellular environment, preemptively binding the misfolded protein and preventing the aggregation of the misfolded client protein in the extracellular space. Furthermore, stress-induced ERdj3 can be secreted on its own into the extracellular space where it can bind to misfolded, aggregation-prone client proteins and attenuate pathologic protein aggregation in the extracellular environment.

extracellular proteostasis through its co-secretion with destabilized, misfolding-prone client proteins. This capacity of ERdj3 to be co-secreted with misfolding-prone proteins avoids the problem of diffusion-limited encounter in the extracellular space.

ERdj3-client co-secretion serves as a natural bridge between the dual roles of ERdj3 as an ER HSP40 and in regulating extracellular proteostasis (Fig 7). In the ER, ERdj3 delivers misfolded clients (e.g., ^{FTTTR^{A25T}}) into the BiP cycle for chaperoning. If inadequate free BiP is available, ERdj3 remains bound to its client protein throughout the secretory pathway and the client-ERdj3 complex can be secreted into the extracellular space, where lack of BiP prevents ERdj3 release from the substrate. When the ER must deal with high, persistent levels of misfolding-prone proteins, the UPR is activated, increasing the levels of ERdj3, BiP and other chaperones to offer

misfolding-prone proteins more ER chaperoning capacity. Simultaneously, increased intracellular ERdj3 is available to bind and co-secrete with misfolding-prone protein clients that evade ER quality control and traverse the secretory pathway, providing preemptive chaperone capacity to the extracellular space. Importantly, clusterin co-secretion, unlike ERdj3 co-secretion, assists destabilized clients in evading ER quality control, providing a potential reason for the reduced secretion of clusterin during conditions of ER stress. Thus, ERdj3 offers a unique link between ER and extracellular proteostasis, employing a mechanism that cannot be achieved with other known secreted chaperones.

The capacity of UPR-dependent activation of ATF6 to influence extracellular proteostasis through ERdj3 secretion indicates a potential role for this pathway in extracellular protein aggregation pathologies. UPR signaling is activated in many extracellular protein aggregation diseases, including Alzheimer's disease and the systemic amyloidoses (Teixeira *et al*, 2006; Saxena *et al*, 2009; Hoozemans *et al*, 2012; Hetz & Mollereau, 2014). Our results showing that secreted ERdj3 can increase the extracellular chaperoning and prevent extracellular aggregation and/or proteotoxicity of disease-associated proteins such as TPrP, TTR^{A25T}, and A β suggest that ATF6-dependent regulation of ERdj3 secretion is a potential mechanism to protect the extracellular space from proteotoxicity. Consistent with this prediction, presenilin mutations causatively associated with Alzheimer's disease significantly impair ATF6 activation during stress (Katayama *et al*, 1999, 2001). Thus, a decreased capacity to regulate extracellular proteostasis through ATF6 activation and consequent ERdj3 secretion could be a contributing factor in the disease pathology of patients harboring these mutations.

We have established that UPR activation directly and adaptively regulates the composition of the extracellular proteostasis network through ERdj3 secretion. In particular, UPR-induced secretion of ERdj3 offers a mechanism for organisms to adapt to the presence of destabilized proteins in the secretory pathway and increase extracellular chaperoning capacity through two mechanisms: (1) the secretion of free ERdj3 available to bind misfolding-prone proteins in the extracellular environment and (2) the co-secretion of ERdj3–client complexes, which preemptively protects the extracellular environment from proteotoxic protein conformations. This potentially provides an endogenous mechanism to prevent ER stress-induced increases in extracellular protein aggregation and proteotoxicity that can lead to degenerative phenotypes. Our identification of ERdj3 as a UPR-induced secreted chaperone demonstrates that targeting adaptive stress responses, particularly the ATF6 arm of the UPR, can enhance the maintenance of extracellular proteostasis, offering a promising approach to better understand and intervene in diseases characterized by extracellular protein aggregation.

Materials and Methods

Ethics statement

The protocol for the murine fasting/refeeding experiments was approved by the Institutional Animal Care and Use Committee of The Scripps Research Institute (TSRI). Non-nutritional bedding was provided so that these mice did not need to be deprived of bedding

during the fast. The protocol for high-fructose diet experiments was reviewed and approved by the Committee on Use and Care of Animals at the Sanford Burnham Medical Research Institute.

Plasmid DNA, shRNA, and antibodies

ERdj3^{WT}, ERdj3^{H53Q}, and ERdj3^{KDEL} overexpression constructs were prepared in the pcDNA3.1(+) vector and Clusterin-HA in the pCIneo.X3HA vector. Plasmid construction is detailed in Supplementary Methods. FT^{TTR}A25T and FT^{TTR}WT are in the pcDNA1 plasmids, as previously reported (Shoulders *et al*, 2013). The FT^{BiP} overexpression plasmid is in the pCMV1 vector. The ERdj3 shRNA GIPZ shRNAmir and non-silencing constructs were purchased from Open BioSystems. Polyclonal antibodies were used to detect ERdj3 (rabbit, Proteintech) and HYOU1 (rabbit, Genetex), while mouse monoclonal anti-tubulin, anti- β -actin, 6E10 anti-A β , and M2 anti-FLAG were from Sigma. M1 anti-FLAG agarose beads and M2 anti-FLAG Dynabeads were from Sigma. Polyclonal rabbit antibody to TTR has been reported previously (Sekijima *et al*, 2005). Mouse monoclonal antibodies against KDEL (Assay Designs), HA (Covance), and BiP (E-4, Santa Cruz) were used. Secondary antibodies were purchased from Li–Cor.

Mammalian cell culture

HEK293T, Huh7, HeLa, HepG2, and CHO cells and derived lines were cultured in DMEM (Invitrogen) with 10% FBS (Gibco) supplemented with Pen/Strep and glutamine. HEK293T were transfected by calcium phosphate deposition, with a medium change the following day, while CHO and SH-SY5Y cells were transfected using X-tremeGENE 9 (Roche). SH-SY5Y cells were cultured similarly with 50:50 DMEM/F12 (Invitrogen). Activating ligands trimethoprim (TMP) (RPI, Illinois, USA) and doxycycline were used at 10 μ M and 1 μ g/ml, respectively. Thapsigargin was added to cell media immediately prior to incubation at the indicated concentrations. Stable lines for APP₇₅₁ or ERdj3 overexpression, or for shRNA knockdown, were established by selection and maintained in 500 μ g/ml G418 or 1 μ g/ml puromycin, respectively. ATF6, XBP1s, and GFP adenoviruses were propagated and applied as reported previously (Shoulders *et al*, 2013).

Metabolic labeling and pulse chase

Following the indicated drug treatments, HEK293^{DAX} and Huh7 cells on poly-D-lysine-coated plates were washed well with PBS and metabolically labeled in pulse medium (DMEM without Cys and Met (Mediatech) with [³⁵S]-Cys/Met (MP Biomedicals, ~0.1 mCi/ml final concentration), 10% 10K MWCO-dialyzed FBS, and supplemented with glutamine and penicillin/streptomycin) for 30 min. Cells were then washed well with pre-warmed media and incubated in pre-warmed complete media for the indicated chase time. After the chase, the media were collected, cells were washed well with PBS and lysed on the plate in RIPA on ice for 20 min, and the lysates centrifuged to remove cellular debris. To ensure complete denaturation, lysates were brought to 1% SDS and 1 mM DTT and boiled at 100°C for 5 min, after which they were diluted to 0.1% SDS and 100 μ M DTT, pre-cleared over sepharose 4B (Sigma) and immunoprecipitated using anti-ERdj3 antibody (Proteintech) on Protein A-conjugated

spharose beads (Invitrogen). Elution was performed by boiling 10 min in 6× Laemmli reducing buffer. Eluates were separated by SDS-PAGE, and the gels dried and exposed to an autoradiography cassette overnight. The cassette was scanned on a Typhoon imager, and band intensities were quantified by densitometry in Image-Quant. Error is presented as SEM of at least three replicates, with *P*-values determined by the Student's two-tailed *t*-test.

Quantitative RT-PCR

The quantitative PCR protocol and primers have been previously described (Shoulders *et al*, 2013). RNA was extracted from cells (RNeasy Mini Kit, Qiagen) and cDNA synthesized from 500 ng of total RNA (QuantiTect Reverse Transcription Kit, Qiagen). qPCR (QuantiTect SYBR Green PCR Kit, Qiagen) on this cDNA was performed (45 cycles of 15 s at 94°C, 30 s at 57°C, 30 s at 72°C) in technical triplicate on an ABI PRISM 7900 System.

Murine experiments

For fasting/refeeding experiments, one male and five female 6-week-old DBA/2J mice, maintained on normal chow (5% fat), were subjected to an 18 h fast with non-nutritional bedding, followed by 12 h on a high-fat (60%) diet (Research Diets) as reported previously (Oyadomari *et al*, 2008). Immediately prior to the fast and at indicated time points, mice were anesthetized with isoflurane and aliquots of serum extracted retro-orbitally. The same population of mice was used for each time point. For the high-fructose diet experiments, either normal chow or a high-fructose diet (60% fructose, TD. 89247, Harlan Teklad; Madison, WI) was given to C57/BI6 for 2 days, 7 days, and 6 weeks, with three to four mice in each experimental group. At each experimental termination point, mice were sacrificed after a 4 h fast and serum and livers were collected for immunoblotting analysis.

TPrP treatment and image analysis

TPrP toxicity assay was performed as described (Zhou *et al*, 2012). OptiMEM I (Life Technologies) with 5% FBS was conditioned on HEK293T-Rex-derived cells for 30 h. Collected media were sterile-filtered and concentrated about 5 fold using an Amicon ultra centrifugal unit with 3 kDa MW cutoff (EMD Millipore). About 1,000 PK1 cells (a subclone of N2a neuroblastoma cells) (Klohn *et al*, 2003) were plated per well in 96-well plates in OptiMEM I (5% FBS), and the media was changed to a mixture of concentrated conditioned media (80 μl) and fresh OptiMEM I with 5% BSA (120 μl, to replenish the nutrients) on the next day. TPrP was prepared as reported (Zhou *et al*, 2012), and a final concentration of 0.6 μg/ml was added to the treatment group in triplicate. The cells were incubated for 3 days and imaged by phase-contrast microscopy. Three images of each well were taken, and image identities were blinded prior to analysis and counting. Counting of cells and of cells with identifiable vacuoles was performed separately by two individuals, who obtained similar results, using the Fiji image processing package (Schindelin *et al*, 2012).

Additional experimental details describing previously reported approaches including immunoblotting (Shoulders *et al*, 2013),

preparation of recombinant ERdj3 and BiP, RNase A affinity precipitation (Petrova *et al*, 2008), Aβ_{1–40} aggregation assays (Du *et al*, 2011), and resazurin assays (Shoulders *et al*, 2013) are available in Supplementary Methods. Error bars from quantitative immunoblotting represent SEM, and associated *P*-values were determined using the two-tailed Student's *t*-test.

Supplementary information for this article is available online:

<http://emboj.embopress.org>

Acknowledgements

The authors are grateful to Prof. Evan Powers, Prof. Joel Buxbaum, Prof. Fernando Palhano, and Dr. Xinyi Li for helpful discussions, and to Mike Saure, Gina Dendle, and Eley Wong for technical assistance. We thank the NIH for supportive grants R21NS079882, R01DK102635 (RLW), R37DK046335 (JWK), R21NS081519 (CIL), R37DK042394, R01DK088227, and R01HL052173 (RJK), Arlene and Arnold Goldstein (RLW), the Ellison Medical Foundation (RLW), the Skaggs Institute for Chemical Biology (JWK), the Lita Annenberg Hazen Foundation (JWK), and the Scripps Research Institute for financial support. JCG was supported by the NHLBI (F32-HL099245) and an AHA postdoctoral fellowship. MDS was supported by an American Cancer Society postdoctoral fellowship. SW was supported by an AHA postdoctoral fellowship.

Author contributions

JCG and SQ contributed equally to this work. JCG, SQ, MDS, JWK, and RLW designed experiments. JCG, SQ, and RLW performed cell biology and biochemistry experiments. MZ and CIL designed and performed prion toxicity experiments. SW and RJK prepared sera from mice fed on a high-fructose diet. LMR prepared recombinant BiP and performed experiments. JCG, SQ, and RLW interpreted experimental results and prepared the manuscript, with comments from all authors.

Conflict of interest

The authors declare that they have no conflict of interest.

References

- Adachi Y, Yamamoto K, Okada T, Yoshida H, Harada A, Mori K (2008) ATF6 is a transcription factor specializing in the regulation of quality control proteins in the endoplasmic reticulum. *Cell Struct Funct* 33: 75–89
- Aguzzi A, Heikenwalder M, Polyminenidou M (2007) Insights into prion strains and neurotoxicity. *Nat Rev Mol Cell Biol* 8: 552–561
- Andreasson C, Rampelt H, Fiaux J, Druffel-Augustin S, Bukau B (2010) The endoplasmic reticulum Grp170 acts as a nucleotide exchange factor of Hsp70 via a mechanism similar to that of the cytosolic Hsp110. *J Biol Chem* 285: 12445–12453
- Araki K, Nagata K (2011) Protein folding and quality control in the ER. *Cold Spring Harb Perspect Biol* 3: a007526
- Behne J, Hendershot LM (2014) The large Hsp70 Grp170 binds to unfolded protein substrates *in vivo* with a regulation distinct from conventional Hsp70s. *J Biol Chem* 289: 2899–2907
- Benyair R, Ron E, Lederkremer GZ (2011) Protein quality control, retention, and degradation at the endoplasmic reticulum. *Int Rev Cell Mol Biol* 292: 197–280
- Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D (2000) Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. *Nat Cell Biol* 2: 326–332

- Bohrmann B, Tjernberg L, Kuner P, Poli S, Levet-Trafit B, Naslund J, Richards G, Huber W, Dobeli H, Nordstedt C (1999) Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. *J Biol Chem* 274: 15990–15995
- Booth C, Koch GL (1989) Perturbation of cellular calcium induces secretion of luminal ER proteins. *Cell* 59: 729–737
- Braakman I, Bulleid NJ (2011) Protein folding and modification in the mammalian endoplasmic reticulum. *Annu Rev Biochem* 80: 71–99
- Buck TM, Wright CM, Brodsky JL (2007) The activities and function of molecular chaperones in the endoplasmic reticulum. *Semin Cell Dev Biol* 18: 751–761
- Buck TM, Kolb AR, Boyd CR, Kleyman TR, Brodsky JL (2010) The endoplasmic reticulum-associated degradation of the epithelial sodium channel requires a unique complement of molecular chaperones. *Mol Biol Cell* 21: 1047–1058
- Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudiniere R (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. *Proc Natl Acad Sci USA* 109: 9629–9634
- Buxbaum JN (2004) The systemic amyloidoses. *Curr Opin Rheumatol* 16: 67–75
- Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceicao IM, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Wilson A, Grogan DR (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. *Neurology* 79: 785–792
- Dancourt J, Barlowe C (2010) Protein sorting receptors in the early secretory pathway. *Annu Rev Biochem* 79: 777–802
- DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, Holtzman DM (2004) ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism *in vivo*. *Neuron* 41: 193–202
- van Dijk KD, Jongbloed W, Heijst JA, Teunissen CE, Groenewegen HJ, Berendse HW, van de Berg WD, Veerhuis R (2013) Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease. *Parkinsonism Relat Disord* 19: 1079–1083
- Donner AJ, Bole DG, Kaufman RJ (1987) The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. *J Cell Biol* 105: 2665–2674
- Du D, Murray AN, Cohen E, Kim HE, Simkovsky R, Dillin A, Kelly JW (2011) A kinetic aggregation assay allowing selective and sensitive amyloid-beta quantification in cells and tissues. *Biochemistry* 50: 1607–1617
- Fewell SW, Travers KJ, Weissman JS, Brodsky JL (2001) The action of molecular chaperones in the early secretory pathway. *Annu Rev Genet* 35: 149–191
- Goodwin EC, Lipovsky A, Inoue T, Magaldi TG, Edwards AP, Van Goor KE, Paton AW, Paton JC, Atwood WJ, Tsai B, DiMaio D (2011) BiP and multiple DNAJ molecular chaperones in the endoplasmic reticulum are required for efficient simian virus 40 infection. *MBio* 2: e00101–e00111
- Gotz J, Eckert A, Matamalas M, Ittner LM, Liu X (2011) Modes of Abeta toxicity in Alzheimer's disease. *Cell Mol Life Sci* 68: 3359–3375
- Guo F, Snapp EL (2013) ERdj3 regulates BiP occupancy in living cells. *J Cell Sci* 126: 1429–1439
- Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol* 8: 101–112
- Hahm E, Li J, Kim K, Huh S, Rogelj S, Cho J (2013) Extracellular protein disulfide isomerase regulates ligand-binding activity of alphaMbeta2 integrin and neutrophil recruitment during vascular inflammation. *Blood* 121: 3789–3800
- Hammarstrom P, Sekijima Y, White JT, Wiseman RL, Lim A, Costello CE, Altland K, Garzuly F, Budka H, Kelly JW (2003) D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? *Biochemistry* 42: 6656–6663
- Harding HP, Zhang Y, Ron D (1999) Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. *Nature* 397: 271–274
- Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskva V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet* 41: 1088–1093
- Hetz C, Mollereau B (2014) Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. *Nat Rev Neurosci* 15: 233–249
- Hoozemans JJ, van Haastert ES, Nijholt DA, Rozemuller AJ, Scheper W (2012) Activation of the unfolded protein response is an early event in Alzheimer's and Parkinson's disease. *Neurodegener Dis* 10: 212–215
- Hoshino T, Nakaya T, Araki W, Suzuki K, Suzuki T, Mizushima T (2007) Endoplasmic reticulum chaperones inhibit the production of amyloid-beta peptides. *Biochem J* 402: 581–589
- Jiang X, Smith CS, Petrassi HM, Hammarstrom P, White JT, Sacchettini JC, Kelly JW (2001) An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. *Biochemistry* 40: 11442–11452
- Jin Y, Awad W, Petrova K, Hendershot LM (2008) Regulated release of ERdj3 from unfolded proteins by BiP. *EMBO J* 27: 2873–2882
- Jin Y, Zhuang M, Hendershot LM (2009) ERdj3, a Luminal ER DnaJ Homologue, Binds Directly to Unfolded Proteins in the Mammalian ER: identification of Critical Residues. *Biochemistry* 48: 41–49
- Jordan PA, Gibbins JM (2006) Extracellular disulfide exchange and the regulation of cellular function. *Antioxid Redox Signal* 8: 312–324
- Katayama T, Imaizumi K, Sato N, Miyoshi K, Kudo T, Hitomi J, Morihara T, Yoneda T, Gomi F, Mori Y, Nakano Y, Takeda J, Tsuda T, Itoyama Y, Murayama O, Takashima A, St George-Hyslop P, Takeda M, Tohyama M (1999) Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. *Nat Cell Biol* 1: 479–485
- Katayama T, Imaizumi K, Honda A, Yoneda T, Kudo T, Takeda M, Mori K, Rozmahel R, Fraser P, George-Hyslop PS, Tohyama M (2001) Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's disease-linked presenilin-1 mutations. *J Biol Chem* 276: 43446–43454
- Kelly JW (1996) Alternative conformations of amyloidogenic proteins govern their behavior. *Curr Opin Struct Biol* 6: 11–17
- Kern J, Untergasser G, Zenzmaier C, Sarg B, Gastl G, Gunsilius E, Steurer M (2009) GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib. *Blood* 114: 3960–3967
- Kim I, Xu W, Reed JC (2008) Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. *Nat Rev Drug Discov* 7: 1013–1030
- Klohn PC, Stoltze L, Flechsig E, Enari M, Weissmann C (2003) A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. *Proc Natl Acad Sci USA* 100: 11666–11671

- Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet* 41: 1094–1099
- Lee AH, Iwakoshi NN, Glimcher LH (2003) XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. *Mol Cell Biol* 23: 7448–7459
- Lee AS (2014) Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. *Nat Rev Cancer* 14: 263–276
- Lodish HF, Kong N (1990) Perturbation of cellular calcium blocks exit of secretory proteins from the rough endoplasmic reticulum. *J Biol Chem* 265: 10893–10899
- Marcinowski M, Holler M, Feige MJ, Baerend D, Lamb DC, Buchner J (2011) Substrate discrimination of the chaperone BiP by autonomous and cochaperone-regulated conformational transitions. *Nat Struct Mol Biol* 18: 150–158
- Martins I, Kepp O, Galluzzi L, Senovilla L, Schlemmer F, Adjemian S, Menger L, Michaud M, Zitvogel L, Kroemer G (2010) Surface-exposed calreticulin in the interaction between dying cells and phagocytes. *Ann N Y Acad Sci* 1209: 77–82
- Massey S, Burrell H, Taylor M, Nemecek KN, Ray S, Haslam DB, Teter K (2011) Structural and functional interactions between the cholera toxin A1 subunit and ERdj3/HEDJ, a chaperone of the endoplasmic reticulum. *Infect Immun* 79: 4739–4747
- Meyne F, Gloeckner SF, Ciesielczyk B, Heinemann U, Krasnianski A, Meissner B, Zerr I (2009) Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. *J Alzheimers Dis* 17: 863–873
- Milojevic J, Esposito V, Das R, Melacini G (2007) Understanding the molecular basis for the inhibition of the Alzheimer's A β -peptide oligomerization by human serum albumin using saturation transfer difference and off-resonance relaxation NMR spectroscopy. *J Am Chem Soc* 129: 4282–4290
- Milojevic J, Raditsis A, Melacini G (2009) Human serum albumin inhibits A β fibrillization through a “monomer-competitor” mechanism. *Biophys J* 97: 2585–2594
- Munro S, Pelham HR (1987) A C-terminal signal prevents secretion of luminal ER proteins. *Cell* 48: 899–907
- Nizard P, Tetley S, Le Drean Y, Watrin T, Le Goff P, Wilson MR, Michel D (2007) Stress-induced retrotranslocation of clusterin/ApoJ into the cytosol. *Traffic* 8: 554–565
- Okamura K, Kimata Y, Higashio H, Tsuru A, Kohno K (2000) Dissociation of Kar2p/BiP from an ER sensory molecule, Ire1p, triggers the unfolded protein response in yeast. *Biochem Biophys Res Commun* 279: 445–450
- Oyadomari S, Harding HP, Zhang Y, Oyadomari M, Ron D (2008) Dephosphorylation of translation initiation factor 2 α enhances glucose tolerance and attenuates hepatosteatosis in mice. *Cell Metab* 7: 520–532
- Peters LR, Raghavan M (2011) Endoplasmic reticulum calcium depletion impacts chaperone secretion, innate immunity, and phagocytic uptake of cells. *J Immunol* 187: 919–931
- Petrova K, Oyadomari S, Hendershot LM, Ron D (2008) Regulated association of misfolded endoplasmic reticulum luminal proteins with P58/DNAJc3. *EMBO J* 27: 2862–2872
- Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE (2009) Biological and chemical approaches to diseases of proteostasis deficiency. *Annu Rev Biochem* 78: 959–991
- Reyes Barcelo AA, Gonzalez-Velasquez FJ, Moss MA (2009) Soluble aggregates of the amyloid-beta peptide are trapped by serum albumin to enhance amyloid-beta activation of endothelial cells. *J Biol Eng* 3: 5
- Rochet JC, Lansbury PT Jr (2000) Amyloid fibrillogenesis: themes and variations. *Curr Opin Struct Biol* 10: 60–68
- Rosenberg ME, Girtan R, Finkel D, Chmielewski D, Barrie A 3rd, Witte DP, Zhu G, Bissler JJ, Harmony JA, Aronow BJ (2002) Apolipoprotein J/clusterin prevents a progressive glomerulopathy of aging. *Mol Cell Biol* 22: 1893–1902
- Sato T, Susuki S, Suico MA, Miyata M, Ando Y, Mizuguchi M, Takeuchi M, Dobashi M, Shuto T, Kai H (2007) Endoplasmic reticulum quality control regulates the fate of transthyretin variants in the cell. *EMBO J* 26: 2501–2512
- Saxena S, Cabuy E, Caroni P (2009) A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. *Nat Neurosci* 12: 627–636
- Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A (2012) Fiji: an open-source platform for biological-image analysis. *Nat Methods* 9: 676–682
- Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM (2011) Plasma clusterin and the risk of Alzheimer disease. *JAMA* 305: 1322–1326
- Schroder M, Kaufman RJ (2005) The mammalian unfolded protein response. *Annu Rev Biochem* 74: 739–789
- Sekijima Y, Hammarstrom P, Matsumura M, Shimizu Y, Iwata M, Tokuda T, Ikeda S, Kelly JW (2003) Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. *Lab Invest* 83: 409–417
- Sekijima Y, Wiseman RL, Matteson J, Hammarstrom P, Miller SR, Sawkar AR, Balch WE, Kelly JW (2005) The biological and chemical basis for tissue-selective amyloid disease. *Cell* 121: 73–85
- Shen J, Chen X, Hendershot L, Prywes R (2002) ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. *Dev Cell* 3: 99–111
- Shen Y, Hendershot LM (2005) ERdj3, a stress-inducible endoplasmic reticulum DnaJ homologue, serves as a cofactor for BiP's interactions with unfolded substrates. *Mol Biol Cell* 16: 40–50
- Shoulders MD, Ryno LM, Genereux JC, Moresco JJ, Tu PG, Wu C, Yates JR 3rd, Su AI, Kelly JW, Wiseman RL (2013) Stress-Independent Activation of XBP1 and/or ATF6 Reveals Three Functionally Diverse ER Proteostasis Environments. *Cell Rep* 3: 1279–1292
- Silajdzic E, Minthon L, Bjorkqvist M, Hansson O (2012) No diagnostic value of plasma clusterin in Alzheimer's disease. *PLoS One* 7: e50237
- Sriburi R, Jackowski S, Mori K, Brewer JW (2004) XBP1: a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. *J Cell Biol* 167: 35–41
- Stefani M, Dobson CM (2003) Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. *J Mol Med (Berl)* 81: 678–699
- Tan YL, Genereux JC, Pankow S, Aerts JM, Yates JR 3rd, Kelly JW (2014) ERdj3 Is an Endoplasmic Reticulum Degradation Factor for Mutant Glucocerebrosidase Variants Linked to Gaucher's Disease. *Chem Biol* 21: 967–976
- Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. *Cell* 120: 545–555
- Teixeira PF, Cerca F, Santos SD, Saraiva MJ (2006) Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from

- transthyretin deposition in familial amyloid polyneuropathy. *J Biol Chem* 281: 21998–22003
- Terada K, Manchikalapudi P, Noiva R, Jauregui HO, Stockert RJ, Schilsky ML (1995) Secretion, surface localization, turnover, and steady state expression of protein disulfide isomerase in rat hepatocytes. *J Biol Chem* 270: 20410–20416
- Walter P, Ron D (2011) The unfolded protein response: from stress pathway to homeostatic regulation. *Science* 334: 1081–1086
- Wang M, Wey S, Zhang Y, Ye R, Lee AS (2009) Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders. *Antioxid Redox Signal* 11: 2307–2316
- Wang S, Chen Z, Lam V, Han J, Hassler J, Finck BN, Davidson NO, Kaufman RJ (2012) IRE1alpha-XBP1s Induces PDI Expression to Increase MTP Activity for Hepatic VLDL Assembly and Lipid Homeostasis. *Cell Metab* 16: 473–486
- Wen KW, Damania B (2010) Hsp90 and Hsp40/Erdj3 are required for the expression and anti-apoptotic function of KSHV K1. *Oncogene* 29: 3532–3544
- Wijsman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, Cheng R, Lee JH, Bird TD, Bennett DA, Diaz-Arrastia R, Goate AM, Farlow M, Ghetti B, Sweet RA, Foroud TM, Mayeux R (2011) Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. *PLoS Genet* 7: e1001308
- Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG (1996) A new variant of Creutzfeldt-Jakob disease in the UK. *Lancet* 347: 921–925
- Wiseman RL, Koulov A, Powers E, Kelly JW, Balch WE (2007) Protein energetics in maturation of the early secretory pathway. *Curr Opin Cell Biol* 19: 359–367
- Wong YH, Lu AC, Wang YC, Cheng HC, Chang C, Chen PH, Yu JY, Fann MJ (2010) Protogenin defines a transition stage during embryonic neurogenesis and prevents precocious neuronal differentiation. *J Neurosci* 30: 4428–4439
- Wu J, Rutkowski DT, Dubois M, Swathirajan J, Saunders T, Wang J, Song B, Yau GD, Kaufman RJ (2007) ATF6alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. *Dev Cell* 13: 351–364
- Wyatt AR, Yerbury JJ, Dabbs RA, Wilson MR (2012) Roles of Extracellular Chaperones in Amyloidosis. *J Mol Biol* 421: 499–516
- Wyatt AR, Yerbury JJ, Ecroyd H, Wilson MR (2013) Extracellular chaperones and proteostasis. *Annu Rev Biochem* 82: 295–322
- Xia W, Zhang J, Kholodenko D, Citron M, Podlisy MB, Teplow DB, Haass C, Seubert P, Koo EH, Selkoe DJ (1997) Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. *J Biol Chem* 272: 7977–7982
- Yamamoto K, Hamada H, Shinkai H, Kohno Y, Koseki H, Aoe T (2003) The KDEL receptor modulates the endoplasmic reticulum stress response through mitogen-activated protein kinase signaling cascades. *J Biol Chem* 278: 34525–34532
- Yamamoto K, Sato T, Matsui T, Sato M, Okada T, Yoshida H, Harada A, Mori K (2007) Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1. *Dev Cell* 13: 365–376
- Yu M, Haslam DB (2005) Shiga toxin is transported from the endoplasmic reticulum following interaction with the luminal chaperone HEDJ/ERdj3. *Infect Immun* 73: 2524–2532
- Zhang Y, Liu R, Ni M, Gill P, Lee AS (2010) Cell surface relocation of the endoplasmic reticulum chaperone and unfolded protein response regulator GRP78/BiP. *J Biol Chem* 285: 15065–15075
- Zhou M, Ottenberg G, Sferrazza GF, Lasmezas CI (2012) Highly neurotoxic monomeric alpha-helical prion protein. *Proc Natl Acad Sci USA* 109: 3113–3118

